Hematologist On Call: Relapsed/Refractory Mantle Cell Lymphoma Post cBTKi

In this podcast episode, Toby A. Eyre, MD, MBChB, and Tycel J. Phillips, MD, FASCO, discuss the evolving treatment landscape of R/R mantle cell lymphoma as covalent BTK inhibitor use further expands into the first-line setting. They highlight the similarities and differences between small molecules pirtobrutinib and sonrotoclax including patient selection, step-up dosing requirements, TLS monitoring, efficacy post covalent BTKi, sequencing, and the feasibility of implementing treatment in community practices. They also examine the dosing, efficacy, and safety of CAR T-cell therapy and bispecific antibodies, establishing their current and possible future roles in R/R MCL.

Presenters:

Toby A. Eyre, MD, MBChB
Hematology Consultant
Department of Hematology
Oxford University Hospitals NHS Trust
Oxford, United Kingdom

Tycel J. Phillips, MD, FASCO
Associate Professor of Medicine
City of Hope National Medical Center
Duarte, California

Link to full program: 
https://bit.ly/4k7Vkrv

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.